Advarra Funds PRIM&R AI Ethics Curriculum for IRBs, Leaving the Agenda to PRIM&R

Advarra is funding a PRIM&R curriculum on AI ethics and governance for research oversight, with PRIM&R holding full editorial control. Here is what it covers, why it matters and what to watch.

The Clinical Trial Vanguard reported on October 11, 2026 that Advarra, which operates institutional review boards (IRBs) and sells clinical trial technology, has funded PRIM&R to build a curriculum on AI ethics and governance for the research oversight community ^[1]. Under the arrangement described, PRIM&R sets the agenda, picks the speakers and keeps full editorial authority, and Advarra's name is absent from the syllabus ^[1]. The piece, by Chief Editor Moe Alsumidaie, links to an Advarra blog post explaining the decision ^[1].

What the program includes

PRIM&R, founded in 1974, serves more than 25,000 individuals across 1,000 institutions in over 30 countries, according to the article ^[1]. The curriculum will run in three formats: a podcast miniseries, a leadership roundtable series culminating at the PRIM&R Annual Conference, and a virtual workshop spanning several days ^[1]. The article ties this range to a gap in resources: IRB professionals at large academic medical centers and at smaller community institutions rarely have matching professional development budgets or conference calendars, and using several formats is presented as the way to reach the smaller institutions ^[1]. The story gives no dates for any of the three formats ^[1].

The questions IRBs are already facing

Per the report, IRBs reviewing studies that use AI-assisted tools already face questions that lack settled answers ^[1]. Two examples are named: how a consent form should describe an algorithm's role, and which safeguards apply when a tool could influence decisions about enrollment eligibility ^[1]. Summarizing Advarra's post, the story says institutions with dedicated technology evaluation staff are working through these questions, while institutions without such staff face them with far less support ^[1]. The article's conclusion is direct: "Field-wide programming is the only mechanism that reaches both." ^[1]

The regulatory backdrop

The article sets the initiative beside the FDA's draft guidance on AI supporting regulatory decision-making, reading it as a sign that governance questions at the institutional level are arriving faster than most oversight bodies have policy frameworks to address them ^[1]. It does not say how the curriculum will relate to that draft guidance ^[1].

Why the funding structure matters

Because Advarra develops AI tools for clinical research, it has a direct commercial stake in how oversight bodies come to interpret AI use, the article notes ^[1]. Paying for an independent curriculum instead of producing one in-house is presented as keeping that conflict out of the education IRB professionals receive ^[1]. The story also characterizes the motive as more practical than altruistic, tied to the open questions IRBs are already handling ^[1].

What to watch

Whether other technology vendors that support ethics education take up the same arm's-length structure, which the article says will reveal something real about the field's appetite for that kind of separation ^[1].
Whether the curriculum, once delivered, takes up the two open questions the article names: consent-form descriptions of an algorithm's role, and safeguards when a tool could influence enrollment eligibility decisions ^[1].
Whether the multi-format delivery reaches IRB professionals at smaller community institutions, the group the article says the range of formats is meant to reach ^[1].
How institutional oversight policies develop alongside the FDA's draft guidance on AI in regulatory decision-making ^[1].